Search

Your search keyword '"Colomer R"' showing total 556 results

Search Constraints

Start Over You searched for: Author "Colomer R" Remove constraint Author: "Colomer R"
556 results on '"Colomer R"'

Search Results

1. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

2. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

5. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

8. Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer

12. Evolución y resultados del tratamiento neoadyuvante en cáncer de mama durante un periodo de 10 años

15. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

16. 1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy

18. Epigenetic regulation of gfi1 in endocrine-related cancers : A role regulating tumor growth

19. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

20. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

21. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

26. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

27. 46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

33. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

37. Real-world treatment in patients with HER2+ metastatic breast cancer

49. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

50. Lateral variations of the midcrustal seismicity in western Nepal: Seismotectonic implications

Catalog

Books, media, physical & digital resources